Zuberitamab (Anruixi)
Jump to navigation
Jump to search
General information
Class/mechanism: Anti-CD20 monoclonal antibody.
Diseases for which it is used
History of changes in NMPA indication
- 2023-09-13: Initial approval for the treatment of CD20-positive diffuse large B-cell lymphoma (DLBCL). (Based on Li et al. 2024)
Also known as
- Code name: HS-006
- Brand name: Anruixi